Agenus (AGEN)
6.19
+0.66 (11.93%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13G AGENUS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
July 20, 2026 4:17 PM - SEC Filing
Agenus (AGEN) files for 2.13M share offering by selling stockholders
July 20, 2026 6:08 AM - StreetInsider
Form S-3 AGENUS INC
July 20, 2026 6:02 AM - SEC Filing
Form SCHEDULE 13G AGENUS INC Filed by: Invus Global Management, LLC
July 17, 2026 4:39 PM - SEC Filing
Agenus to present BOT+BAL cancer data at ESMO 2026 congress
July 17, 2026 10:28 AM - StreetInsider
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
July 17, 2026 10:28 AM - BizWire
Form 4 AGENUS INC For: Jul 10 Filed by: ARMEN GARO H
July 14, 2026 3:30 PM - SEC Filing
Agenus Inc. (AGEN) PT Raised to $30 at H.C. Wainwright
July 13, 2026 12:16 PM - StreetInsider
Agenus rises premarket; Micron, Western Digital slide
July 13, 2026 6:33 AM - StreetInsider
Form 8-K AGENUS INC For: Jul 13
July 13, 2026 6:31 AM - SEC Filing
Agenus raises up to $340M to fund MSS colon cancer Phase 3 trial
July 13, 2026 6:00 AM - StreetInsider
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
July 13, 2026 6:00 AM - BizWire
Form 4 AGENUS INC For: Jul 01 Filed by: HARRISON THOMAS L
July 7, 2026 10:48 AM - SEC Filing
Form 4 AGENUS INC For: Jul 01 Filed by: Wright Timothy
July 7, 2026 10:42 AM - SEC Filing
Form 8-K AGENUS INC For: Jun 29
July 6, 2026 4:11 PM - SEC Filing
Agenus reports 3-year survival data for colorectal cancer drug combo
July 6, 2026 7:31 AM - StreetInsider
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
July 6, 2026 7:30 AM - BizWire
Form 4 AGENUS INC For: Jun 26 Filed by: ARMEN GARO H
June 30, 2026 6:06 AM - SEC Filing
Agenus to present 3-year colorectal cancer survival data at ESMO GI
June 25, 2026 7:00 AM - StreetInsider
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
June 25, 2026 7:00 AM - BizWire
Form 8-K AGENUS INC For: Jun 16
June 23, 2026 10:14 AM - SEC Filing
Form 4 AGENUS INC For: Jun 12 Filed by: ARMEN GARO H
June 16, 2026 9:00 AM - SEC Filing
Agenus Announces Virtual 2026 Annual Shareholders Meeting
June 2, 2026 4:30 PM - BizWire
Form 4 AGENUS INC For: May 29 Filed by: ARMEN GARO H
June 2, 2026 6:09 AM - SEC Filing
Agenus reports AI analysis shows improved response rates for cancer treatment
May 21, 2026 5:00 PM - StreetInsider
Agenus reports melanoma trial data for drug combination BOT+BAL
May 21, 2026 5:00 PM - StreetInsider
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
May 21, 2026 5:00 PM - BizWire
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
May 21, 2026 5:00 PM - BizWire
Form 4 AGENUS INC For: May 15 Filed by: ARMEN GARO H
May 19, 2026 5:01 PM - SEC Filing
Form 8-K AGENUS INC For: May 12
May 15, 2026 4:13 PM - SEC Filing
Agenus publishes phase 1b data for liver cancer drug combination
May 15, 2026 4:11 PM - StreetInsider
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
May 15, 2026 4:11 PM - BizWire
Form DEFA14A AGENUS INC
May 13, 2026 2:59 PM - SEC Filing
Form 10-Q AGENUS INC For: Mar 31
May 11, 2026 5:05 PM - SEC Filing
Form 8-K AGENUS INC For: May 11
May 11, 2026 8:52 AM - SEC Filing
Agenus reports $4.6 million in pre-commercial revenue for Q1 2026
May 11, 2026 8:45 AM - StreetInsider
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
May 11, 2026 8:45 AM - BizWire
Form 4 AGENUS INC For: May 01 Filed by: ARMEN GARO H
May 5, 2026 5:49 PM - SEC Filing
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
May 4, 2026 4:30 PM - BizWire
Form ARS AGENUS INC For: Dec 31
April 30, 2026 4:37 PM - SEC Filing
Form DEF 14A AGENUS INC For: Apr 30
April 30, 2026 4:35 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: O'Day Steven J
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: Buell Jennifer
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: Wright Timothy
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: Charette Austin
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: HARRISON THOMAS L
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: Hirsch Susan B
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: Corvese Brian
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: ARMEN GARO H
April 28, 2026 4:15 PM - SEC Filing
Full Article List
